Edition:
United Kingdom

Adaptimmune Announces Favorable Review Of Safety From One Billion Cell Dose Cohort In Mage-A10 Spear T-Cell Study


Wednesday, 18 Jul 2018 

July 18 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE ANNOUNCES FAVORABLE REVIEW OF SAFETY FROM ONE BILLION CELL DOSE COHORT IN MAGE-A10 SPEAR T-CELL STUDY AND INITIATION OF THIRD DOSING COHORTS.ADAPTIMMUNE THERAPEUTICS PLC - SAFETY REVIEW COMMITTEE ENDORSED DOSE ESCALATION TO THIRD DOSE COHORTS IN BOTH MAGE-A10 PILOT STUDIES.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN REPORTED. 

Company Quote

3.63
-0.09 -2.42%
8:21pm BST